News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
Aridis Pharmaceuticals Granted FDA Agreement for Single Confirmatory Phase 3 Study of AR-301 and Reveals Clinical Study Design
Saturday, July 01, 2023Aridis Pharmaceuticals Inc Nasdaq ARDS has received positive feedback from the FDA regarding its proposed Phase study for investigational monoclonal antibody candidate AR The study aims to evaluate the antibody as an adjunctive therapy in combinatio...
Temferon™ Granted Orphan Drug Designation by European Commission for Glioma Treatment
Friday, June 30, 2023Genenta Science NASDAQ GNTA has recently received Orphan Drug Designation ODD from the European Commission for their product Temferon which is being developed for the treatment of glioma specifically Glioblastoma Multiforme GBM ODD is granted to drug...
BioNTech and OncoC4 Collaborate on Phase 3 Trial for BNT316/ONC-392 Program in Metastatic NSCLC
Friday, June 30, 2023BioNTech SE Nasdaq BNTX and OncoC Inc have jointly announced the initiation of a Phase clinical trial for their novel antiCTLA antibody candidate BNTONC gotistobart The trial aims to evaluate the effectiveness and safety of BNTONC as a standalone th...
Societal CDMO and Civicascript Establish Master Service Agreement for CDMO Services
Friday, June 30, 2023Societal CDMO Inc NASDAQ SCTL has recently entered into a master service agreement MSA with CivicaScript a significant development in the contract development and manufacturing organization CDMO sector Societal CDMO is dedicated to addressing complex...
Alloy Therapeutics Introduces Exclusive Anticlastic™ Antisense Oligonucleotide Platform for the Creation of Powerful Genetic Medications
Thursday, June 29, 2023Alloy Therapeutics has recently unveiled its innovative AntiClastic Antisense Oligonucleotide AntiClastic ASO platform which enhances the properties of antisense therapeutics by employing optimally designed spatial conformation nucleic acids The comp...
Foghorn Therapeutics Unveils Clinical Findings From Phase 1 Trial of FHD-286 in Metastatic Uveal Melanoma
Thursday, June 29, 2023Foghorn Therapeutics Inc Nasdaq FHTX has released data from a Phase dose escalation safety study of their drug candidate FHD in metastatic uveal melanoma mUM The study aimed to evaluate the safety and tolerability of FHD However the company has deci...
Amicus Therapeutics Unveils Newly Approved Pompe Disease Therapy in the European Union
Wednesday, June 28, 2023Amicus Therapeutics a biotechnology company dedicated to developing medicines for rare diseases has received approval from the European Commission EC for Opfolda miglustat mg capsules Opfolda is an enzyme stabilizer used in the treatment of lateonset...
UCB Receives FDA Approval for RYSTIGGO® (Rozanolixizumab-noli) to Treat Adults With Generalized Myasthenia Gravis
Wednesday, June 28, 2023UCB a global biopharmaceutical company has received FDA approval for RYSTIGGO rozanolixizumabnoli as a treatment for generalized myasthenia gravis gMG in adult patients who are antiacetylcholine receptor AchR or antimusclespecific tyrosine kinase MuS...
AC Immune Granted FDA Fast Track Designation for ACI-24.060, an Anti-amyloid-beta Active Immunotherapy, in the Treatment of Alzheimer's Disease
Wednesday, June 28, 2023AC Immune SA a biopharmaceutical company specializing in precision medicine for neurodegenerative diseases has announced that its antiamyloid beta Abeta active immunotherapy candidate ACI has received Fast Track designation from the US Food and Drug...
Avicanna and Medipharm Labs Enhance Collaborative Manufacturing Agreement for Avicanna's Proprietary SEDDS Technology Capsules in Canadian and Global Markets
Tuesday, June 27, 2023Avicanna Inc a biopharmaceutical company focused on plantderived cannabinoidbased products has announced an extension of its strategic manufacturing agreement with Medipharm Labs Inc The agreement aims to commercialize Avicannas proprietary cannabino...
